66th ASH Annual Meeting: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster II

Symposia: Cellular Immunotherapies other than CAR-T Cells: Basic and Translational Oral and Poster Abstracts
Poster

Research, Acute Myeloid Malignancies, Combination therapy, AML, Fundamental Science, Adult, Translational Research, Assays, Elderly, Bioinformatics, Plasma Cell Disorders, Diseases, Cell expansion, Treatment Considerations, Biological therapies, Immunology, Immunotherapy, Lymphoid Malignancies, Biological Processes, Myeloid Malignancies, Technology and Procedures, Gene editing, Miscellaneous Cellular Therapies, Study Population, Natural Killer (NK) Cell Therapies, Human, Transplantation (Allogeneic and Autologous)

Halls G-H (San Diego Convention Center)

3434

Engineered-NK Cells Expressing Chimeric Ilt Receptors (CIR™) Expand and Eliminate Bone Marrow-Resident HLA-G⁺ AML in NSG Mice

Mylinh Duong, PhD^*, Jihyun Park, PhD^*, Joseph Senesac, MSc, MBA^*, Raphael Ognar, MSc, MBA, Simon Wain-Hobson, DPhil^* and Henri Bayle, PhD

NKILT Therapeutics, Houston, TX

3435

Developing Novel Cellular Therapies for Cutaneous T Cell Lymphoma (CTCL): Combining Immunopeptidomics and Endogenous T Cell (ETC) Therapy Platforms to Identify and Target Shared CTCL-Associated Antigens

Casey Bermack, MD, PhD¹, Ke Pan, PhD²^*, Yulun Chiu, PhD²^*, Luis Malpica, MD¹^*, Swaminathan P Iyer, MD¹^*, Christopher R. Flowers, MD, MS¹ and Cassian Yee, MD²^*

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

3436

Targeting the Membrane-Proximal Domain of CD33 to Maximize the Efficacy of Natural Killer Cell-Based Immunotherapies

Sheryl Y. T. Lim, DPhil¹^*, Frances M. Cole¹^*, George S. Laszlo, PhD²^*, Margaret C. Lunn-Halbert¹^*, Jenny Huo¹^*, Junyang Li¹^*, Allie R. Kehret¹^* and Roland B. Walter, MD, PhD, MS^3,4,5

¹Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
²1100 Fairview Avenue North, Fred Hutchinson Cancer Center, Seattle, WA
³Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA
⁴Fred Hutchinson Cancer Center, Seattle, WA
⁵Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA

3437

Natural Killer and Gamma Delta T Cells Derived from Engineered Induced Pluripotent Stem Cells Have Potent Preclinical Activity to Treat B Cell-Mediated Autoimmune Diseases

Diana Chin, MS^*, Andriana Lebid, Ph.D.^*, Kaitlin Idank^*, Mark Mendonca^*, Arina Perez^*, Nicholas Alexander^*, Steven DeLuca^*, Charles Dominick^*, Buddha Gurung, Ph.D.^*, Barry Morse, Ph.D.^*, Liam Campion, MS^*, Daniel Perry, Ph.D.^*, Michael Naso, Ph.D.^*, Hy Levitsky, MD and Hillary Quinn, MS^*

Century Therapeutics, Philadelphia, PA

3438

NK-like Skewing As the Key Driver of T Cell Dysfunction in AML: Implications for Enhancing TCR-T Cell Therapy Efficacy

Francesco Mazziotta, MD, PhD¹, Lauren E Martin¹^*, Daniel Eagan, MD¹^*, Filippo Milano, MD², Valentin Voillet¹^*, Tzu-Hao Tang¹^*, Miranda Lahman, PhD¹^*, Sinéad Kinsella, MSc, PhD¹^*, Kelly Paulson, MD, PhD³^*, Philip D Greenberg, MD¹^* and Aude G Chapuis, MD¹

¹Fred Hutchinson Cancer Center, Seattle, WA
²Fred Hutchinson Cancer Research Center, Seattle, WA
³Swedish Cancer Institute Medical Oncology, Seattle

3439

Improved Expansion of Peripheral Blood and iPSC-Derived Natural Killer Cells for Clinical Applications

Jaya Lakshmi Thangaraj, M.Tech, PhD.¹^*, Edith Lopez²^* and Dan S Kaufman, MD, PhD³

¹Department of Medicine, Division of Regenerative Medicine, University of California San Diego, San Diego, CA
²Department of Medicine, Division of Regenerative Medicine, University of California, San Diego, San Diego, CA
³University of California San Diego, La Jolla, CA

3440

Structurally Optimized, IL-2-Armored CLL1 CAR-NK Cells Are Highly Potent Effectors Against AML without Hpsc Toxicity

David N. Sedloev, MD¹^*, Qian Chen²^*, Julia M. Unglaub, MD³^*, Anita Schmitt, MD⁴^*, Carsten Müller-Tidow, MD^3,5^*, Michael Schmitt, MD⁴^* and Tim Sauer, MD³

¹Heidelberg Myeloma Center, Department of Medicine V, Heidelberg University Hospital, Heidelberg, AL, Germany
²Heidelberg University Hospital, Heidelberg, Germany
³Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
⁴Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
⁵European Molecular Biology Lab (EMBL), Molecular Medicine Partnership Unit, Heidelberg, Germany

3441

L-Arginine Reinforces NK Cell-Mediated GVL Effect in Bone Marrow of AML Patients with Early Relapse Post-Allo-HSCT

Dongyao Wang, PhD^1,2,3^*, Chuang Yuan⁴^*, Yue Wu⁵^*, Xingchi Chen⁵^*, Guangyu Sun⁶^*, Aijie Huang, MD⁷^*, Xiaoyu Zhu^8,9 and Haiming Wei, MD¹⁰^*

¹Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei City, Anhui Province, China
²Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA
³Institute of Immunology, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei, China
⁴Peking University, Beijing, China
⁵Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China, Hefei, China
⁶Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Heifei, China
⁷The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Shanghai, China
⁸Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China
⁹Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
¹⁰Institute of Immunology, School of Basic Medicine and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China., Hefei, CHN

3442

CRISPR/Cas9 Multi-Editing Enhances CAR NK Cells Therapeutic Potential Against Multiple Myeloma

Eva Castellano¹^*, Almudena García-Ortiz, PhD¹^*, Laura Ugalde, PhD²^*, Elena Maroto Martin, PhD¹^*, Jessica Encinas Mayoral, PhD¹^*, Raquel Oliva¹^*, Laura Garcia-Garcia²^*, Irene Peña²^*, Noemi Álvarez¹^*, Gonzalo Carreño, PhD³^*, Rosa Ayala, MD, PhD⁴^*, Laura Cordoba¹^*, Alejandra Leivas, PhD¹^*, Guillermo Suñe⁵^*, Beatriz Martin Antonio, PhD⁶^*, Rafael Alonso Fernandez, MD⁷^*, Maria Teresa Cedena Romero, MD, PhD¹^*, Joaquín Martínez-Lopez⁴^*, Paula Rio, PhD² and Antonio Valeri, PhD¹^*

¹Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC, Madrid, Spain
²Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Biomedical research center in rare disease netwotk (CIBERER) and Fund Jiménez Díaz Research Institute, Madrid, Spain
³Hospital Universitario 12 de Octubre, Madrid, Spain
⁴Department of Translational Hematology, Research Institute Hospital 12 de Octubre (i+12), Hematological Malignancies Clinical Research Unit H120-CNIO, CIBERONC, Madrid, Spain, Madrid, Spain
⁵Clinic Barcelona Hospital/IDIBAPS, Department of Hematology, ICMHO, Barcelona, Spain, Madrid, Spain
⁶Department of Experimental Hematology, Fundación Jiménez Díaz research institute, Madrid, Spain., Madrid, Spain
⁷Department of Hematology, Hospital Universitario 12 de Octubre-Universidad Complutense, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain

3443

Engineering Synergistic Adoptive Cell Therapies for Enhanced Treatment of Acute Myeloid Leukemia

Valentina Grillo Alvarado, BS^1,2^*, Ryma Toumi, PhD²^*, Aidan Schutte³^*, Aitong Ruan²^* and Shannon Oda, PhD²

¹Molecular and Cellular Biology Graduate Program, University of Washington, Seattle
²Seattle Children's Research Institute, Seattle, WA
³University of Washington, Seattle

3444

Dual Inhibition of Histone and DNA Methylation in AML Enhances the Effectiveness of TCR-Based Cellular Therapy through Upregulation of Surface MHC Class I/p53 Antigen Complex

Ulrike Regina Schmits¹^*, Edite Antunes Ferreira²^*, Borhane Guezguez, PhD^2,3^*, David Gomez-Zepeda^4,5^*, Stefan Tenzer^4,5,6^*, Kevin Jan Legscha²^*, Matthias Theobald, MD^3,6,7 and Hakim Echchannaoui, PhD^2,3^*

¹Department of Hematology and Medical Oncology, University Medical Center (UMC) Mainz, Mainz, AL, Germany
²Department of Hematology and Medical Oncology, University Medical Center (UMC) Mainz, Mainz, Germany
³German Cancer Consortium (DKTK), Partner site Frankfurt/Mainz, Mainz, Germany
⁴Helmholtz Institute for Translational Oncology Mainz (HI-TRON Mainz), Mainz, Germany
⁵DKFZ German Cancer Research Center, Heidelberg, Germany
⁶Institute of Immunology, Research Center for Immunotherapy (FZI), Mainz, Germany
⁷Department of Hematology and Oncology, Medical Center of the Johannes Gutenberg University, Mainz, Germany

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH